Genzyme Targets InvaGen Over Kidney Treatment Generics

Law360, New York (March 16, 2012, 4:33 PM ET) -- Genzyme Corp. sued InvaGen Pharmaceuticals Inc. on March 12 in New York, in an attempt to prevent the company from making and marketing generic versions of chronic kidney disease medications Renagel and Renvela.

Genzyme brought the complaint to defend its $700 million share of the kidney disease treatment market from enroaching generics. It claims that InvaGen's treatment would violate its patented drug composition and deflate the demand for its own products.

Genzyme says it received a letter from InvaGen in January notifying the company of a...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required